Agetech startup SILVIA Health announced that the Chosun University consortium, in which it participated as a joint research institute, was finally selected for the '2025 Korean ARPA-H Project' hosted by the Ministry of Health and Welfare, the Korea Health Industry Development Institute, and the K-Health Future Promotion Group.
With this selection, Sylvia Health will co-lead a national strategic research and development project with a government budget of up to 12.75 billion won over the next five years. Sylvia Health will serve as the lead agency for commercialization and validation, responsible for developing an AI-based, personalized prevention and management service based on the risk of cognitive decline.
The selected project, "Development of Personalized Brain Cognitive Function Decline Prevention and Slowdown Services Based on the Brain Cognitive Reserve Foundation Model (ABC-H)," is a key project within the welfare and care sector of the Korean ARPA-H program. This project, with a total budget of KRW 1.1628 trillion, will be implemented from 2024 to 2032. Its goals include establishing a multimodal foundation model based on the concept of brain cognitive reserve and utilizing it to develop risk-based, personalized services.
The study focuses on establishing a foundation for multifaceted assessment of the possibility of cognitive decline, and aims to secure a basis for responding to the increasing burden of care in a super-aged society by incorporating AI analysis technology and daily life-related management services.
This project will be led by the Chosun University Industry-Academic Cooperation Foundation, with six other institutions participating as joint R&D institutions: the Seoul National University Industry-Academic Cooperation Foundation, BioNexus, the AI Industry Convergence Business Unit, Silvia Health, and Chonnam National University Hospital. The research project will focus on the development and validation of a dementia prevention AI care service based on a large-scale brain, omics, and language foundation model.
The research team plans to leverage the Gwangju Dementia Cohort (GARD) data, accumulated over 12 years, as a core resource to implement a single, integrated research stream that encompasses a large-scale, long-term cohort, a multimodal AI model, and real-world user-based preventive services. Silvia Health will play a key role in this process, focusing on reviewing the applicability of research findings to services and user accessibility.
Within the consortium, Silvia Health will be responsible for the validation portion, applying the core technologies and AI models developed by research institutes to real-world applications and transforming them into services accessible to the public. The company will leverage its experience operating B2B and B2G services, including cognitive health management solutions like SILVIA Wellness and SILVIA Station, to verify the field suitability of its research findings.
Silvia Health plans to gradually expand the scope of its public health applications by linking future AI-based solutions with its existing solution lineup.
- See more related articles
You must be logged in to post a comment.